Avalyn is developing inhaled therapies for people with severe and rare respiratory diseases.

Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow disease progression but are associated with significant side effects, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled medicines to reduce systemic exposure and deliver the medication directly to the disease site. AP01, Avalyn’s lead candidate, is a Phase 2b-ready inhaled formulation of pirfenidone optimized for direct lung delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve efficacy and safety over existing therapy.

Learn more about this approach and our therapeutic focus.

Lyn Baranowski photo

Lyn Baranowski

Chief Executive Officer

Melissa Rhodes, Ph.D., D.A.B.T photo

Melissa Rhodes, Ph.D., D.A.B.T

Chief Operating Officer

Howard M. Lazarus, M.D., FCCP photo

Howard M. Lazarus, M.D., FCCP

Chief Medical Officer

Marc Schneebaum photo

Marc Schneebaum

Chief Financial Officer

Mark Surber, Ph.D. photo

Mark Surber, Ph.D.

Founder and Chief Scientific Officer

Michelle Patterson photo

Michelle Patterson

Senior Vice President, Program Management

Stephen Pham, Ph.D. photo

Stephen Pham, Ph.D.

Senior Vice President, Product Development

Nancy McKinley photo

Nancy McKinley

Senior Vice President, Administration & Finance

Niall O’Donnell, Ph.D. photo

Niall O’Donnell, Ph.D.

Chairman, Managing Director, RiverVest Venture Partners

Tiba Aynechi photo

Tiba Aynechi

General Partner, Norwest Venture Partners

Sofia Ioannidou, Ph.D. photo

Sofia Ioannidou, Ph.D.

Director (Life Sciences), Andera Partners

Jonathan Leff, M.D. photo

Jonathan Leff, M.D.

Independent Director

David Malek photo

David Malek

General Partner, Pivotal bioVenture Partners

Peter Moldt, Ph.D. photo

Peter Moldt, Ph.D.

Partner, Novo Ventures (US), Inc.

Ketan Patel, M.D. photo

Ketan Patel, M.D.

Partner, F-Prime Capital

Lyn Baranowski photo

Lyn Baranowski

Chief Executive Officer

Andera Partners Investor LogoF/Prime Investor LogoNorwest Investor LogoNovo Investor Logo

Pivotal Bioventure Partners Investor LogoRivervest Investor LogoTPG Investor Logo


With family history of IPF, Founder Mark Surber conceives of inhaled pirfenidone (AP01)


First AP01 Patent Filed &

Avalyn Incorporated


First AP01 Publication

AP01 US Orphan Drug Designation for the treatment of IPF


$62M Series A Complete


AP01 Phase 1a Complete


First Inhaled Nintedanib (AP02) Publication

$35M Series B Complete


AP01 Phase 1b POC Complete

AP02 Phase 1a Complete

AP01 EU Orphan Drug Designation for the treatment of IPF


AP01 Phase 2b Design & Series C Fund Raising